Potential "first-in-class" targeted protein degradation agents enter the clinic

On October 6, 2021, Dialectic Therapeutics announced that the first-generation compound DT2216, constructed based on its proprietary new anti-apoptotic protein targeted degradation technology (APTaD), has completed the first patient administration in a phase 1 clinical trial.

Preclinical studies have shown that DT2216 can selectively induce the degradation of BCL-XL protein in cancer cells

Picture source: reference [2]

This multi-center, dose-escalating phase 1 clinical trial is aimed at patients with advanced/metastatic solid tumors and hematological malignancies, who no longer respond to approved or standard treatments

Reference materials:

[1] Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216, its First Generation Antiapoptotic Protein Targeted Degradation (APTaD™) Compound, in Patients with Relapsed or Refractory Malignancies.

[2] Pal, P.

(The original text has been deleted)